Makeover sees Viatris move further away from generics
The speciality group will soon be without biosimilars; in the meantime it's buying two companies with patent-protected medicines.
Looking for winners in geographic atrophy
NGM’s NGM621 now looks like a dead end, but there are plenty of others hoping for a piece of this market, including Roche and Lineage.
Syncona sets its sights on a gene therapy turnaround
But, with Applied Genetic Technologies Corporation, can lightning strike a third time?
